TriSalus Life Sciences Q2 revenue beats estimates

TriSalus Life Sciences

06/08/2026 21:32

Overview
Oncology device maker's Q2 revenue rose yr/yr, beating analyst expectations
Company maintained 2026 revenue guidance of $54 mln to $57 mln
Operating losses widened due to higher sales and marketing expenses

Outlook
TriSalus maintains 2026 revenue guidance of $54 mln to $57 mln
Company expects further growth in the second half of 2026 and beyond

Result Drivers
SALES AND MARKETING EXPENSES - Operating losses increased mainly due to higher sales and marketing costs from expanding the sales organization
GROSS MARGIN IMPROVEMENT - Gross margin rose to 86.8% from 83.9% a year earlier, mainly due to lower cost per TriNav unit

Company press release: ID:nBw2Mdwqfa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$11.41 mln
$10.27 mln (4 Analysts)
Q2 Gross Profit
 
$9.90 mln
 
Q2 Income from Operations
 
-$9.81 mln
 
Q2 Pretax Loss
 
$9.18 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $9.00, about 94.8% above its August 5 closing price of $4.62

Reuters Recommended Reads
Aug 6 - Delcath Systems Q2 revenue rises, beats estimates
Aug 6 - CG Oncology Q2 net loss widens on higher R&D costs
Aug 5 - Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)